tbuckley/cabot-search huggingface dataset:
Abstract 17166: Comparison Between Use of Vasoactive Medications in Patients Undergoing PVC and VT Ablation
Authors: Amneet Sandhu, Jeffrey Graham, Alexis Tumolo, Blake Fleeman, Nicholas Mantini, Michael Rosenberg, Wendy Tzou, William H Sauer, Duy T Nguyen
Journal: Circulation (2018)

Background: Societal guidelines have set prerequisites regarding procedures conducted in the EP lab. Despite metrics for management of EP cases, no clear guidelines exist for use of hemodynamic drugs to support complex ablations, particularly in setting of structural heart disease. Objectives: We sought to understand the variety and range of vasoactive medication use in patients undergoing PVC/VT ablation. Methods: Patients undergoing PVC or VT ablation, from January 2015 to December 2016, at our institution were analyzed. Demographics, echocardiography, and procedural details, including vasoactive medication use, were analyzed. Results: Sequential patients undergoing PVC or VT ablation (70 in each arm) were studied. Those undergoing PVC ablation (56 +/- 14 years, 30% female) had an average EF of 58% in comparison to 44% (p&lt;0.01 for EF difference) in VT ablation patients (60 +/- 13 years, 20% female); more VT patients (62%) were under general anesthesia. Pressors were administered in 86% of cases with the significant majority (63%) consisting of alpha-agonists (phenylephrine, ephedrine, epinephrine). Importantly, 48% of cases required continuous drip initiation (Figure). Regardless of case type or abnormal EF, drip initiation with or administration of multiple bolus doses of alpha-agonists was much more frequent compared to inotropes (Figure). In a subset of patients with EF ≤ 35%, 96% received vasoactive medications with 73% receiving a continuous drip or multiple bolus doses of phenylephrine. Conclusions: Vasoactive medication use during ventricular EP cases is common. Regardless of baseline EF, a propensity for use of alpha-agonists exists that may affect the treatment of patients with abnormal LV function. More studies are needed to assess the impact of pressor use on patient safety and procedural endpoints in the EP lab. Figure:
Murine Epsins Play an Integral Role in Podocyte Function
Authors: Ying Wang, Christopher E. Pedigo, Kazunori Inoue, Xuefei Tian, Elizabeth Cross, Karen Ebenezer, Wei Li, Zhen Wang, Jee Won Shin, Eike Schwartze, Marwin Groener, Shuta Ishibe
Journal: Journal of the American Society of Nephrology (2020)

Significance Statement When podocytes are injured, foot processes efface and detach, leading to severe proteinuria. Endocytic trafficking maintains the integrity of this crucial glomerular interface. Epsins, a family of membrane proteins, assist in the endocytosis and also take part in cell signaling. Mice that have lost podocyte-associated epsins develop proteinuria and kidney failure, due to diminished activity of the transcription factor serum response factor (SRF), which reduces cell division control protein 42 homolog activation and β 1 integrin expression. Podocyte-specific Srf knockout mice also demonstrate proteinuria and kidney failure. These findings suggest that, in podocytes, epsins are required to coordinate a proper signaling platform, beyond their known endocytic properties. Background Epsins, a family of evolutionarily conserved membrane proteins, play an essential role in endocytosis and signaling in podocytes. Methods Podocyte-specific Epn1 , Epn2 , Epn3 triple-knockout mice were generated to examine downstream regulation of serum response factor (SRF) by cell division control protein 42 homolog (Cdc42). Results Podocyte-specific loss of epsins resulted in increased albuminuria and foot process effacement. Primary podocytes isolated from these knockout mice exhibited abnormalities in cell adhesion and spreading, which may be attributed to reduced activation of cell division control protein Cdc42 and SRF, resulting in diminished β 1 integrin expression. In addition, podocyte-specific loss of Srf resulted in severe albuminuria and foot process effacement, and defects in cell adhesion and spreading, along with decreased β 1 integrin expression. Conclusions Epsins play an indispensable role in maintaining properly functioning podocytes through the regulation of Cdc42 and SRF-dependent β 1 integrin expression.
Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021
Authors: Shirley LL Kwok, Samuel MS Cheng, Jennifer NS Leung, Kathy Leung, Cheuk-Kwong Lee, JS Malik Peiris, Joseph T Wu
Journal: Eurosurveillance (2022)

The mRNA vaccine Comirnaty and the inactivated vaccine CoronaVac are both available in Hong Kong’s COVID-19 vaccination programme. We observed waning antibody levels in 850 fully vaccinated (at least 14 days passed after second dose) blood donors using ELISA and surrogate virus neutralisation test. The Comirnaty-vaccinated group’s (n = 593) antibody levels remained over the ELISA and sVNT positive cut-offs within the first 6 months. The CoronaVac-vaccinated group’s (n = 257) median antibody levels began to fall below the cut-offs 4 months after vaccination.
Manuscripts Approved for JNCI, March 10 to April 10, 1964
Journal: JNCI Journal of the National Cancer Institute (1964)

Manuscripts Approved for JNCI, March 10 to April 10, 1964 JNCI: Journal of the National Cancer Institute, Volume 32, Issue 5, May 1964, Page 1200, https://doi.org/10.1093/jnci/32.5.1200 Published: 01 May 1964
CC-BY Open Access Added
Journal: JAMA Neurology (2021)

Hannah C. Glass, MDCM, MAS; Janet S. Soul, MDCM; Taeun Chang, MD; Courtney J. Wusthoff, MD, MS; Catherine J. Chu, MD; Shavonne L. Massey, MD; Nicholas S. Abend, MD, MSCE; Monica Lemmon, MD; Cameron Thomas, MD, MS; Adam L. Numis, MD; Ronnie Guillet, MD, PhD; Julie Sturza, MPH; Nancy A. McNamara, MD; Elizabeth E. Rogers, MD; Linda S. Franck, RN, PhD; Charles E. McCulloch, PhD; Renée A. Shellhaas, MD, MS
Committee on Foods
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis
Authors: Amar U Kishan, Yilun Sun, Holly Hartman, Thomas M Pisansky, Michel Bolla, Anouk Neven, Allison Steigler, James W Denham, Felix Y Feng, Almudena Zapatero, John G Armstrong, Abdenour Nabid, Nathalie Carrier, Luis Souhami, Mary T Dunne, Jason A Efstathiou, Howard M Sandler, Araceli Guerrero, David Joseph, Philippe Maingon, Theo M de Reijke, Xavier Maldonado, Ting Martin Ma, Tahmineh Romero, Xiaoyan Wang, Matthew B Rettig, Robert E Reiter, Nicholas G Zaorsky, Michael L Steinberg, Nicholas G Nickols, Angela Y Jia, Jorge A Garcia, Daniel E Spratt
Journal: The Lancet Oncology (2022)
Zika Virus
Authors: Lyle R. Petersen, Denise J. Jamieson, Ann M. Powers, Margaret A. Honein
Journal: New England Journal of Medicine (2016)

n 1947, a study of yellow fever yielded the first isolation of a new virus, from the blood of a sentinel rhesus macaque that had been placed in the Zika Forest of Uganda. 1 Zika virus remained in relative obscurity for nearly 70 years; then, within the span of just 1 year, Zika virus was introduced into Brazil from the Pacific Islands and spread rapidly throughout the Americas. 2It became the first major infectious disease linked to human birth defects to be discovered in more than half a century and created such global alarm that the World Health Organization (WHO) would declare a Public Health Emergency of International Concern. 3 This review describes the current understanding of the epidemiology, transmission, clinical characteristics, and diagnosis of Zika virus infection, as well as the future outlook with regard to this disease. Epidemiol ogyZika virus is a flavivirus, in the family Flaviviridae.Although Zika virus was isolated on several occasions from Aedes africanus mosquitoes after its discovery in 1947, 4 there initially was no indication that the virus caused human disease.Nevertheless, a serosurvey involving residents of multiple areas of Uganda revealed a 6.1% seroprevalence of antibodies against Zika virus, which suggested that human infection was frequent. 5Additional serosurveys indicated a much broader geographic distribution of human infection, including Egypt, 6 East Africa, 7 Nigeria, 8 India, 9 Thailand, 10 Vietnam, 10 the Philippines, 11 and Malaysia (near Kuala Lumpur and in East Malaysia [Sabah and Federal Territory of Labuan]). 12uman illness caused by Zika virus was first recognized in Nigeria in 1953, when viral infection was confirmed in three ill persons. 8Despite recognition that Suburban-UrbanMosquito
Contents
Authors: Tai Vu, Eva Fenwick, Alfred Gan, Ryan Man, Benjamin Tan, Preeti Gupta, Kam Ho, Carlos Reyes-Ortiz, Stella Trompet, Jacobijn Gussekloo, Joan O'brien, Sigrid Mueller-Schotte, Tien Wong, Yih Tham, Ching-Yu Cheng, Allen Lee, Greta Rait, Bonnielin Swenor, Varshini Varadaraj, Willa Brenowitz, Felipe Medeiros, Virginie Naël, Kaavya Narasimhalu, Christopher Chen, Ecosse Lamoureux, Ayub Qassim, Sean Mullany, Farshad Abedi, Henry Marshall, Mark Hassall, Antonia Kolovos, Lachlan Knight, Thi Nguyen, Mona Awadalla, Angela Chappell, Angela Bappsci, Anna Schulz, Ashish Galanopoulos, Paul Healey, Alex Hewitt, Stuart Graham, John Landers, Robert Casson, Owen Dphil, Jamie Siggs, Darryl Nousome, Roberta Mckean-Cowdin, Grace Richter, Bruce Burkemper, Mina Torres, Rohit Varma, Avyuk Dixit, Jithin Yohannan, Michael Boland, Rahul Khurana, Derek Kunimoto, Young Yoon, Charles Wykoff, Andrew Chang, Raj Maturi, Hansjürgen Agostini, Eric Souied, David Chow, Andrew Lotery, Masahito Ohji, Francesco Bandello, Rubens Belfort, Xiao-Yan Li, Jenny Jiao, Grace Le, Kimmie Kim, Werner Schmidt, Yehia Hashad, Johanna Colijn, Magda Meester-Smoor, Timo Verzijden, Anita De Breuk, Rufino Silva, Benedicte Merle, Audrey Cougnard-Grégoire, Carel Hoyng, Sascha Fauser, Anthonius Coolen, Catherine Creuzot-Garcher, Hans-Werner Hense, Marius Ueffing, Cecile Delcourt, Anneke Den Hollander, Caroline Klaver, Jordi Monés, Sunil Srivastava, Glenn Jaffe, Ramin Tadayoni, Thomas Albini, Peter Kaiser, Frank Holz, Jean-Francois Korobelnik, Ivana Kim, Christian Pruente, Timothy Murray, Jeffrey Heier, Annette Hoskin, V Dinesh, Rupesh Agrawal, Reply Chen, Gerald Mcgwin, Grant Justin, Fasika Woreta
Journal: Ophthalmology (2021)
Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRAS<sup>G12D </sup>siRNA in patients with metastatic pancreatic cancer harboring a KRAS<sup>G12D</sup> mutation.
Authors: Rishi Surana, Valerie S. LeBleu, J. Jack Lee, Brandon George Smaglo, Dan Zhao, Michael Sangmin Lee, Robert A. Wolff, Michael J. Overman, Mayela C. Mendt, Kathleen M. McAndrews, Sujuan Yang, Katy Rezvani, Raghu Kalluri, Anirban Maitra, Elizabeth J. Shpall, Shubham Pant
Journal: Journal of Clinical Oncology (2022)

TPS633 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with few effective therapeutic options. Over 90% of patients with PDAC harbor activating mutations in KRAS, a known oncogenic driver of tumor growth, cancer cell survival and metastasis thus making for an attractive therapeutic target. However, targeting the most common KRAS mutations in pancreatic cancer (KRAS G12D and KRAS G12V ) remains a pharmacological challenge. Exosomes are extracellular nano-vesicles that are efficiently internalized by target cells and are under investigation as a drug-delivery vehicle for various therapeutic payloads, including nucleic acids such as small interfering RNA (siRNA). Previously published pre-clinical data demonstrate effective delivery of exosomes loaded with siRNA targeting KRAS G12D leading to tumor control in various murine models of PDAC. Methods: This is a single arm, single institution, phase I trial evaluating treatment with KRAS G12D -siRNA loaded exosomes. Large-scale production of KRAS G12D -siRNA loaded exosomes from mesenchymal stromal cells will be performed at the MD Anderson Cancer Center using pre-specified GMP-compliant protocols. The primary endpoints of this study are to determine a maximum tolerated dose (MTD) of KRAS G12D -loaded exosomes and to identify dose-limiting toxicities (DLT). Key secondary endpoints include the pharmacokinetics of circulating exosomes, overall response rate, disease control rate (defined as partial responses and patients with stable disease), median progression-free survival (PFS) and median overall survival (OS). Key inclusion criteria include histologically confirmed metastatic pancreatic ductal adenocarcinoma, documented progression on one or more lines of systemic therapy, and documented presence of a KRAS G12D mutation. Selected correlative studies include measurement of circulating siRNA and KRAS G12D DNA using PCR. This trial will enroll up to 28 patients and will follow a 3+3 design for dose escalation. This trial is actively accruing and has enrolled six patients at the time of submission. Clinical trial information: NCT03608631.
An Address Delivered at the Opening of the Section of Obstetric Medicine
Authors: C. J. Cullingworth
Journal: BMJ (1889)

tained hopes which, if they could be with us to-day, they would sorrowfully admit had never been realised.I am sure they would say that they fully expected a large proportion of the insane under the reformed treatment to be permanently cured of their malady, and never for an instant supposed that of those who should recover, a frightful proportion would relapse, and that, seventy years after the opening of the first pauper asylum in Yorkshire, there would be five large county and one borough asylum in addition to that at York.I venture to say that had it been pos- sible for them to have foreseen this, their astonishment and dismay would have been great indeed; and, were they present at this moment, it would seriously temper the satisfaction they might
Erratum. Comment on Choi et al. Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study. Diabetes Care 2021;44:1393–1401
Authors: Tsung-Kun Lin, Ya-Hui Lin, Gwo-Ping Jong
Journal: Diabetes Care (2022)
Tremelimumab (day 1 only) and durvalumab in combination with transarterial chemoemobilization (TACE) in patients with hepatocellular carcinoma (HCC).
Authors: Jemma Buchalter, Iseult Browne, Colm Mac Eochagain, Calvin Flynn, Hailey Kathryn Carroll, Marie Galligan, Michele Bourke, Amy Lester-Grant, Fiona Desmond, Katherine Hoey, Ronan Ryan, Colin P Cantwell, Jeffrey McCann, Ray McDermott, Ross MacNicholas, Austin G Duffy
Journal: Journal of Clinical Oncology (2022)

451 Background: TACE induces a peripheral anti-tumor immune response, which may be amplified by immune checkpoint inhibitors (ICI). Combining TACE with dual ICI therapy has been shown to be safe and feasible. Recent data has suggested that Day 1-only anti-CTLA4 dosing could potentially lead to a stronger immune response with a tolerable safety profile though this novel schedule has not previously been combined with TACE. Methods: Patients with HCC (Childs Pugh A/B7, Barcelona clinic liver cancer stage B/C; ECOG 0/1; sorafenib-naive or experienced) were enrolled in a pilot study of tremelimumab at 2 dose levels (DL1: 75mg IV q4-weekly x 4 and DL2: 300mg IV D1 only) in combination with durvalumab (1500mg IV q-28d) and TACE (D36 +/- 96 hours) until progression of disease (per irRECIST) or off-study criteria. Peripheral immune monitoring was performed and tumor biopsies were obtained at time of TACE. Results: 13 patients enrolled on study; N = 3 at DL1 and N = 10 at DL2. M:F 10:3. Median age 70 (65-74). BCLC B/C 4/9. Extrahepatic disease 6/7. Aetiology: NASH (N = 3), alcohol-related disease (N = 1), HCV (N = 2), hemochromatosis (N = 1), unknown (N = 6). 1 patient discontinued due to G3 colitis. All patients evaluable for response with 2/10 patients on DL2 experiencing PR (at 8 weeks) and overall 8/13 SD and 3/13 PD as best response. Updated PFS and OS data to be presented. Conclusions: Tremelimumab (Day 1 only) and Durvalumab in combination with TACE is safe and feasible in patients with HCC. Follow-up is ongoing and full safety and efficacy data will be presented. Clinical trial information: 2019-002767-98.
TCT-481 Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE
Authors: Fausto Feres, Fernando S. Devito, Ricardo A. Costa, Alexandre Abizaid, Martin Leon, Roberto Botelho, Spencer King, Marco A. Perin, Rodolfo Staico, Jose d Costa, Andrea Abizaid, Deepak L. Bhatt
Journal: Journal of the American College of Cardiology (2014)
Early changes in coronary flow reserve of the culprit vessel after primary PTCA for acute myocardial infarction in patients with no regional contractile improvement at hospital discharge - relationship with viability Phillippe Garot, Olivier Pascal, Marc Simon, Emmanuel Teiger, Pascal Gu�ret, Jean-Luc Dubois-Rand�, Patrick Dupouy. Hopital Henri Mondor, Cr�teil, France
Journal: Journal of the American College of Cardiology (2001)
Should we vaccinate children against SARS-CoV-2?
Authors: None The Lancet Infectious Diseases
Journal: The Lancet Infectious Diseases (2021)

Following sharing with regulatory bodies of phase 3 trial data showing that Pfizer-BioNTech's mRNA BNT162b2 vaccine was efficacious, immunogenic, and safe in children aged 12–15 years, several countries have authorised the use of the vaccine in this age group. Reactions to this news have been mixed. Although it is considered likely that children will have to be vaccinated against SARS-CoV-2 eventually, there is the question of whether now is the right time. Many public health figures think not, considering that children typically experience only mild illness and many of the world's low-income and middle-income countries (LMICs) are reporting vaccine shortages.
Error in Discussion Section
Authors: Yoni Ashar, Tor Wager
Journal: JAMA Psychiatry (2022)

Sonia Bansal, PhD; Gi-Yeul Bae, PhD; Benjamin M. Robinson, BA; Britta Hahn, PhD; James Waltz, PhD; Molly Erickson, PhD; Pantelis Leptourgos, PhD; Phillip Corlett, PhD; Steven J. Luck, PhD; James M. Gold, PhD
The National Hospital for the Paralysed and Epileptic
Authors: J. H. Jackson, T. Buzzard, R. B. Carter, H. C. Bastian, W. R. Gowers, D. Ferrier, J. A. Ormerrod, C. E. Beevor, H. H. Tooth, J. Taylor, J. S. R. Russell, W. A. Turner, F. E. Batten, F. Semon, V. Horsley, C. A. Ballance, R. M. Gunn, A. E. Cumberbatch
Journal: BMJ (1900)
Abstract P355: Socioeconomic Factors and Race Negatively Impact Performance Based Motor Skills Following Stroke: Evidence From the Health and Retirement Study
Authors: Joy N Buie
Journal: Circulation (2018)

Background: Evidence suggests that racial and ethnic minorities consistently have poorer post-stroke functional outcomes. Hypothesis: We hypothesized that race in addition to socioeconomic status (SES) would correlate with poorer measures of functional outcomes in stroke patients. Methods: Our aim was to identify factors that contribute to disparate functional outcomes among middle- and retirement-aged non-Hispanic whites (white) and non-Hispanic African Americans (AA). Through retrospective analysis of data from the Health and Retirement Study (HRS), we analyzed 2,831 respondents who reported incident stroke between 1999 and 2014. Respondents were asked to report perceived difficulty with gross and fine motor function and basic activities of daily living (ADL). Linear and logistic regression analysis determined independent predictors of post-stroke motor function and ADL. Results: The analysis included 2,314 (82%) whites and 517 (18%) AA adults with stroke. The AA median age was 71± 11.3 while the white median age was 76 ± 10.5 (p&lt;0.0001). Factors associated with more difficulty with ADL, fine motor function, and gross motor function included older age, female gender, AA race, and higher numbers of household residents. Surprisingly, the comorbidity score was only associated with difficulty in gross motor function. Moreover, the time since stroke did not associate with any performance measure. Increased difficulty with performance-based ADL, fine, and gross motor skills in AAs relative to whites, was associated with younger age, more residents in the home, and less household income. Although our analysis was limited due to the lack of long-term follow-up in the HRS study, these data can help direct future stroke recovery health disparity studies. Conclusions: Our findings highlight the importance of examining contributing factors to racial disparities in post stroke outcomes.